The Asia-Pacific nanomedicines market is projected to grow at a modest CAGR of 10.9% during the forecast period (2021-2027). The major aspect that drives the growth of the market includes the rise in the prevalence of life-threatening diseases along with the demand for effective treatment solutions. Besides, the rapid development of healthcare infrastructure and growth in health awareness among the population are also some major factors that accelerate the demand for the proper treatment solutions and in turn, contribute to the growth of the market. Further, China and India are expected to contribute substantially to the Asia-Pacific nanomedicines market owing to the rising number of researches going on in the economies.
The Asia-Pacific nanomedicines market is segmented on the basis of indication type and application. Based on the indication type, the market is segmented as cardiovascular diseases, neurological diseases, infectious diseases, oncological diseases, orthopedic diseases, and others. The other segment includes urological disease and ophthalmic diseases. The cardiovascular diseases segment is likely to hold a substantial share in the market over the forecast period. Based on the applications, the market is segmented as drug delivery, active implants, vaccines, diagnostic imaging, biomaterials, regenerative medicines, and other applications. The other segment includes tissue regeneration. The drug delivery segment is likely to hold a substantial share in the market over the forecast period.
Based on the demographic viewpoint, the Asia-Pacific nanomedicine market is segmented into China, India, Japan, ASEAN, South Korea, and the Rest of Asia-Pacific. China and India are projected to hold a significant market share over the forecast period owing to various R&D activities conducted by the key players. Further, 3M Co., Johnson & Johnson Services Inc., Merck & Co. Inc., Thermo Fisher Scientific Inc., AstraZeneca Plc., Celgene Corp., Pfizer Inc., Sanofi SA, and Smith & Nephew Plc among others are some of the prominent players functioning in the Asia-Pacific Nanomedicine market. New product launches & developments, partnerships, agreements, and acquisitions are some of the growth strategies adopted by the players in order to sustain in the highly competitive market.
RESEARCH METHODOLOGY
The market study of the Asia-Pacific nanomedicine market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.
Secondary sources include:
The report is intended for nanomedicine companies, healthcare companies, research institutes and universities, other related companies, and government organizations for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions.
Market Segmentation:
The Report covers:
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Competitive Dashboard
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Asia-Pacific Nanomedicine Market by Indication Type
5.1.1. Cardiovascular Diseases
5.1.2. Neurological Diseases
5.1.3. Infectious Diseases
5.1.4. Oncological Diseases
5.1.5. Orthopedic Diseases
5.1.6. Other Diseases (Urological Disease, Ophthalmic Diseases)
5.2. Asia-Pacific Nanomedicine Market by Application
5.2.1. Drug Delivery
5.2.2. Active Implants
5.2.3. Vaccines
5.2.4. Diagnostic Imaging
5.2.5. Biomaterials
5.2.6. Regenerative Medicines
5.2.7. Other Applications (Tissue Regeneration)
6. Regional Analysis
6.1. Asia-Pacific
6.1.1. China
6.1.2. India
6.1.3. Japan
6.1.4. ASEAN
6.1.5. South Korea
6.1.6. Rest of Asia-Pacific
7. Company Profiles
7.1. 3M Co.
7.2. AstraZeneca Plc.
7.3. Celgene Corp.
7.4. Ferro Corp.
7.5. GE Global Research
7.6. Johnson & Johnson Services Inc.
7.7. Luminex Corp.
7.8. Merck & Co. Inc.
7.9. PerkinElmer Inc.
7.10. Pfizer Inc.
7.11. Sanofi SA
7.12. Smith & Nephew Plc
7.13. St. Jude Medical Inc.
7.14. Stryker Corp.
7.15. Taiwan Liposome Co. Ltd.
7.16. Thermo Fisher Scientific Inc.
1. ASIA-PACIFIC NANOMEDICINE MARKET RESEARCH AND ANALYSIS BY INDICATION TYPE, 2020-2027 ($ MILLION)
2. ASIA-PACIFIC NANOMEDICINES FOR CARDIOVASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
3. ASIA-PACIFIC NANOMEDICINES FOR NEUROLOGICAL DISEASES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
4. ASIA-PACIFIC NANOMEDICINES FOR INFECTIOUS DISEASES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
5. ASIA-PACIFIC NANOMEDICINES FOR ONCOLOGICAL DISEASES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
6. ASIA-PACIFIC NANOMEDICINES FOR ORTHOPEDIC DISEASES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
7. ASIA-PACIFIC NANOMEDICINES FOR OTHER DISEASES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
8. ASIA-PACIFIC NANOMEDICINE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
9. ASIA-PACIFIC DRUG DELIVERY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
10. ASIA-PACIFIC ACTIVE IMPLANTS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
11. ASIA-PACIFIC VACCINES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
12. ASIA-PACIFIC DIAGNOSTIC IMAGING MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
13. ASIA-PACIFIC BIOMATERIALS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
14. ASIA-PACIFIC REGENERATIVE MEDICINES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
15. ASIA-PACIFIC OTHER APPLICATIONS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
16. ASIA-PACIFIC NANOMEDICINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
17. CHINA NANOMEDICINE MARKET RESEARCH AND ANALYSIS BY INDICATION TYPE, 2020-2027 ($ MILLION)
18. CHINA NANOMEDICINE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
19. INDIA NANOMEDICINE MARKET RESEARCH AND ANALYSIS BY INDICATION TYPE, 2020-2027 ($ MILLION)
20. INDIA NANOMEDICINE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
21. JAPAN NANOMEDICINE MARKET RESEARCH AND ANALYSIS BY INDICATION TYPE, 2020-2027 ($ MILLION)
22. JAPAN NANOMEDICINE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
23. ASEAN NANOMEDICINE MARKET RESEARCH AND ANALYSIS BY INDICATION TYPE, 2020-2027 ($ MILLION)
24. ASEAN NANOMEDICINE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
25. SOUTH KOREA NANOMEDICINE MARKET RESEARCH AND ANALYSIS BY INDICATION TYPE, 2020-2027 ($ MILLION)
26. SOUTH KOREA NANOMEDICINE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
27. REST OF ASIA-PACIFIC NANOMEDICINE MARKET RESEARCH AND ANALYSIS BY INDICATION TYPE, 2020-2027 ($ MILLION)
28. REST OF ASIA-PACIFIC NANOMEDICINE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
1. ASIA-PACIFIC NANOMEDICINE MARKET SHARE BY INDICATION TYPE, 2020 VS 2027 (%)
2. ASIA-PACIFIC NANOMEDICINE MARKET SHARE BY APPLICATION, 2020 VS 2027 (%)
3. ASIA-PACIFIC NANOMEDICINE MARKET SHARE BY COUNTRY, 2020 VS 2027 (%)
4. CHINA NANOMEDICINE MARKET SIZE, 2020-2027 ($ MILLION)
5. INDIA NANOMEDICINE MARKET SIZE, 2020-2027 ($ MILLION)
6. JAPAN NANOMEDICINE MARKET SIZE, 2020-2027 ($ MILLION)
7. ASEAN NANOMEDICINE MARKET SIZE, 2020-2027 ($ MILLION)
8. SOUTH KOREA NANOMEDICINE MARKET SIZE, 2020-2027 ($ MILLION)
9. REST OF ASIA-PACIFIC NANOMEDICINE MARKET SIZE, 2020-2027 ($ MILLION)